Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$6.83 USD
+0.10 (1.49%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.84 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FULC 6.83 +0.10(1.49%)
Will FULC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FULC
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
New Strong Buy Stocks for November 12th
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fulcrum Before Q3 Earnings: How Should Investors Play the Stock?
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
Pacira's Exparel Receives Permanent New Product-Specific J-Code
Other News for FULC
RBC Capital Maintains Rating and Raises Price Target for Fulcrum Therapeutics (FULC) | FULC ...
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug
FULC Stock: Fulcrum Therapeutics Upgraded to Buy by HC Wainwright | FULC Stock News
Fulcrum Therapeutics (FULC) Receives Upgrade to Buy with Price Target Set at $12